I think 2-3 X is way to underdone. If you look at the 2024 FY results for TLX as an example their revenue to value (Market Cap) was just over 8 times.
But to satisfy the various levels of comfort please see the below:
Assumptions:
- Diagnosed Market Size = 7M Patients
- Revenue per script is $600
- Annual Review per Patient is $7200 based 12 scripts per year
- USD to AUD Exchange rate @ today is $1.48
You will see I have columns for 4X, 6X, 8X, 10X (select your own level of comfort or customise as you see fit).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.015(5.26%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.0¢ | 28.5¢ | $2.754M | 9.333M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30000 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 755655 | 13 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |